Elevation of nortriptyline plasma levels after cotreatment with paroxetine and thioridazine.
Ghaemi
S N
SN
Kirkwood
C K
CK
D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage / Q000009:adverse effects*; D000929:Antidepressive Agents, Tricyclic / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D002851:Chromatography, High Pressure Liquid; D003865:Major Depressive Disorder / Q000097:blood / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D009661:Nortriptyline / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D017374:Paroxetine / Q000008:administration & dosage / Q000009:adverse effects*; D011569:Psychiatric Status Rating Scales; D013881:Thioridazine / Q000008:administration & dosage / Q000009:adverse effects*
D018687:Antidepressive Agents, Second-Generation; D000929:Antidepressive Agents, Tricyclic; D014150:Antipsychotic Agents; D017374:Paroxetine; D009661:Nortriptyline; D013881:Thioridazine